Qiagen : Despite slightly lower FY 2023 guidance Qiagen’s key pillars of growth continue to perform
>Non-Covid product group sales increased by 9% in Q2 2023 - Q2 figures were basically in line with our and the consensus estimates. Reported EBIT came in at $ 105m (y-o-y -13.9%) compared with our estimates of $ 104m, adj. EBIT of $ 136m was -6.8% below the previous year’s figure but above our ($ 131m) and the consensus estimates of $ 134m. Adj. EPS of $ 0.51 was in line with Q2 2022 and the consensus and slightly below our estimate of $ 0.52. Compared with the compan...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.